Novartis on track to deliver Influenza A (H1N1) vaccine for the US
- Details
- Category: Novartis
Novartis has shipped over 7.5 million doses of Influenza A(H1N1)[1] vaccine ready to use and expects 25 to 30 million doses of unadjuvanted vaccine to become available in pre-filled syringes and multi-dose vials by the end of November. Smaller changes in delivery timelines and volumes can result out of the variability of the underlying biological production process. The deliveries are in line with commitments made to the US Department of Health and Human Services (HHS).
Novel agent for treatment of Parkinson's disease - Lu 02-750
- Details
- Category: Lundbeck
H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. The placebo-controlled study is expected to enrol around 100 healthy individuals.
Novo Nordisk increased operating profit by 30% in the first nine months of 2009
- Details
- Category: Novo Nordisk
Sales increased by 15% in Danish kroner and by 11% in local currencies:
-
Sales of modern insulins increased by 28% (24% in local currencies).
Sales of NovoSeven® increased by 15% (11% in local currencies).
Sales of Norditropin® increased by 15% (9% in local currencies).
Sales in North America increased by 29% (17% in local currencies).
Sales in International Operations increased by 18% (16% in local currencies).
AstraZeneca PLC Third Quarter & Nine Months Results 2009
- Details
- Category: AstraZeneca
Revenue in the third quarter increased by 10 percent at CER, but was up 5 percent on an actual basis as a result of the negative impact of exchange rate movements. Revenue benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors and from revenues from US government orders for vaccine for Novel Influenza A (H1N1); adjusting for these factors, global revenue increased by 5 percent.
Abbott completes acquisition acquisition of privately held eye care company Visiogen
- Details
- Category: Abbott
Abbott (NYSE: ABT) has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients.
Forest Laboratories, Inc. and Gedeon Richter Announce Results from a Phase IIb Study of Cariprazine
- Details
- Category: Clinical Trials
Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.
Pandemrix data in an elderly population
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that this week, approximately half a million people will have received its pandemic H1N1 vaccine, Pandemrix™, as part of Government initiated vaccination programmes across Europe, which commenced earlier this month. GSK also announced new results from a clinical trial assessing the use of Pandemrix in adults aged 18 to 85 years of age.
More Pharma News ...
- Boehringer Ingelheim Animal Health closes deal to acquire Animal Health Business from Pfizer
- Novartis delivers strong new product momentum and operational performance
- Merck Revenues Increase by 2.7% to € 1.9 Billion
- FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity
- Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement
- Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer
- Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer